Empowered Funds LLC Purchases 1,796 Shares of Masimo Co. (NASDAQ:MASI)

Empowered Funds LLC grew its position in shares of Masimo Co. (NASDAQ:MASI) by 85.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,891 shares of the medical equipment provider’s stock after acquiring an additional 1,796 shares during the quarter. Empowered Funds LLC’s holdings in Masimo were worth $643,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Lecap Asset Management Ltd. bought a new stake in shares of Masimo during the fourth quarter valued at approximately $1,607,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Masimo by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 373,705 shares of the medical equipment provider’s stock valued at $61,773,000 after acquiring an additional 1,522 shares in the last quarter. Calamos Advisors LLC bought a new stake in shares of Masimo during the fourth quarter valued at approximately $2,691,000. Trust Point Inc. bought a new stake in shares of Masimo during the fourth quarter valued at approximately $230,000. Finally, Greenleaf Trust bought a new stake in shares of Masimo during the fourth quarter valued at approximately $208,000. Institutional investors own 85.96% of the company’s stock.

Masimo Stock Down 0.5 %

MASI stock opened at $180.36 on Wednesday. The stock’s fifty day simple moving average is $172.65 and its two-hundred day simple moving average is $150.39. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $183.14. The stock has a market cap of $9.66 billion, a P/E ratio of 124.39 and a beta of 1.02.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, January 22nd. Piper Sandler upped their price target on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Raymond James upped their price target on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Wells Fargo & Company upped their price target on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Masimo currently has an average rating of “Moderate Buy” and an average price target of $191.40.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.